Table 2.
Baseline characteristics between stroke and non-stroke patients after propensity matched with age, gender, history of stroke, diabetes mellitus, hypertension, smoking family history of coronary artery disease.
| Total N = 608 | No CV event N = 576 | Ischaemic stroke N = 32 | P value | Total N = 171 | No CV event N = 162 | Intracranial haemorrhage N = 9 | P value | |
| Epidemiologic data | ||||||||
| Age, yrs | 67.54 ± 11.83 | 67.44 ± 11.88 | 69.44 ± 10.99 | .351 | 64.73 ± 15.73 | 64.26 ± 15.72 | 73.22 ± 14.11 | .096 |
| Male, n (%) | 513 (84.38%) | 486 (84.38%) | 27 (84.38%) | 1.000 | 152 (88.89%) | 144 (88.89%) | 8 (88.89%) | 1.000 |
| BMI, Kg/m2 | 26.23 ± 3.84 | 26.23 ± 3.85 | 26.2 ± 3.58 | .971 | 26.25 ± 3.93 | 26.31 ± 3.99 | 25.14 ± 2.49 | .387 |
| SBP, mm Hg | 131.24 ± 17.85 | 131.07 ± 17.73 | 134.13 ± 19.98 | .347 | 129.22 ± 17.2 | 129.26 ± 17.31 | 128.44 ± 16.06 | .891 |
| DBP, mmHg | 74.2 ± 11.71 | 74.1 ± 11.65 | 76.06 ± 12.72 | .356 | 73.92 ± 11.68 | 74.12 ± 11.6 | 70.22 ± 13.24 | .331 |
| LVEF, % | 67.54 ± 11.83 | 67.44 ± 11.88 | 69.44 ± 10.99 | .351 | 61.27 ± 14.25 | 61.2 ± 14.5 | 62.33 ± 10.97 | .895 |
| Previous stroke, % | 18 (2.96%) | 17 (2.95%) | 1 (3.13%) | .955 | 11 (6.43%) | 10 (6.17%) | 1 (11.11%) | .557 |
| Family history of CAD, n (%) | 132 (21.71%) | 125 (21.70%) | 7 (21.88%) | .982 | 35 (20.47%) | 33 (20.37%) | 2 (22.22%) | .893 |
| Diabetes mellitus, n (%) | 234 (38.49%) | 221 (38.37%) | 13 (40.63%) | .798 | 65 (38.01%) | 60 (37.04%) | 5 (55.56%) | .265 |
| Hypertension, n (%) | 444 (73.03%) | 420 (72.92%) | 24 (75.00%) | .796 | 112 (65.50%) | 107 (66.05%) | 5 (55.56%) | .519 |
| Smoking, n (%) | 359 (59.05%) | 339 (58.85%) | 20 (62.50%) | .683 | 108 (63.16%) | 101 (62.35%) | 7 (77.78%) | .350 |
| Laboratory data | ||||||||
| Hgb, mg/dL | 13.64 ± 1.79 | 13.67 ± 1.77 | 12.96 ± 1.95 | .033 | 13.38 ± 1.8 | 13.39 ± 1.79 | 13.26 ± 2.02 | .827 |
| Fasting sugar, mg/dL | 120.64 ± 40.94 | 119.82 ± 39.8 | 135.28 ± 56.61 | .137 | 118.71 ± 40.1 | 118.54 ± 40.72 | 121.67 ± 28.47 | .821 |
| Creatinine, mg/dL | 1.2 ± 0.85 | 1.17 ± 0.78 | 1.73 ± 1.66 | .066 | 1.31 ± 1.43 | 1.32 ± 1.47 | 1.12 ± 0.2 | .135 |
| eGFR, mL/min/1.73m2 | 73.68 ± 25.66 | 74.34 ± 25.41 | 61.86 ± 27.62 | .007 | 73.9 ± 25.94 | 74.17 ± 26.43 | 69.07 ± 14.86 | .568 |
| Cholesterol, mg/dL | 161.72 ± 35.32 | 161.7 ± 35.21 | 162.16 ± 37.86 | .943 | 156.48 ± 32.28 | 156.94 ± 32.88 | 148.33 ± 17.78 | .438 |
| TG, mg/dL | 134.37 ± 80.77 | 134.18 ± 79.66 | 137.87 ± 100.55 | .842 | 130.08 ± 75.61 | 131.46 ± 77.17 | 105.44 ± 31.28 | .049 |
| HDL-C, mg/dL | 42.18 ± 10.71 | 42.18 ± 10.73 | 42.15 ± 10.51 | .987 | 40.68 ± 9.83 | 40.66 ± 9.72 | 41.1 ± 12.28 | .897 |
| LDL-C, mg/dL | 93.64 ± 29.31 | 93.92 ± 29.5 | 88.67 ± 25.61 | .324 | 89.59 ± 29.69 | 89.79 ± 30.26 | 86.01 ± 17.46 | .711 |
| Medications | ||||||||
| Statin use, n (%) | 444 (73.03%) | 426 (73.96%) | 18 (56.25%) | .028 | 122 (71.35%) | 115 (70.99%) | 7 (77.78%) | .661 |
| RAS blockade, n (%) | 416 (68.42%) | 394 (68.40%) | 22 (68.75%) | .967 | 121 (70.76%) | 112 (69.14%) | 9 (100.00%) | .048 |
| ACEI, n (%) | 133 (21.88%) | 122 (21.18%) | 11 (34.38%) | .079 | 35 (20.47%) | 34 (20.99%) | 1 (11.11%) | .475 |
| ARB, n (%) | 286 (47.04%) | 275 (47.74%) | 11 (34.38%) | .140 | 87 (50.88%) | 79 (48.77%) | 8 (88.89%) | .019 |
| Antiplatelets, n (%) | 566 (93.09%) | 536 (93.06%) | 30 (93.75%) | .880 | 157 (91.81%) | 149 (91.98%) | 8 (88.89%) | .742 |
| Anticoagulants, n (%) | 14 (2.30%) | 12 (2.08%) | 2 (6.25%) | .126 | 6 (3.51%) | 5 (3.09%) | 1 (11.11%) | .203 |
| Beta-blocker, n (%) | 395 (64.97%) | 374 (64.93%) | 21 (65.63%) | .936 | 108 (63.16%) | 104 (64.20%) | 4 (44.44%) | .232 |
| Biomarkers | ||||||||
| hsCRP, mg/dL | 0.36 ± 1.19 | 0.37 ± 1.22 | 0.3 ± 0.53 | .627 | 0.37 ± 0.75 | 0.4 ± 0.78 | 0.16 ± 0.15 | .031 |
| Adiponectin, ng/mL | 8298.03 ± 13806.29 | 8307.89 ± 14224.07 | 8174.13 ± 6779.52 | .936 | 9651.5 ± 18398.11 | 9980.76 ± 19348.29 | 6688.13 ± 3451.39 | .208 |
| LpPLa2, ng/mL | 163.19 ± 285.52 | 152.15 ± 255.34 | 302 ± 526.46 | .189 | 138.42 ± 242.95 | 133.39 ± 221.26 | 183.75 ± 408.6 | .741 |
| IL6, pg/mL | 3.06 ± 5.03 | 3.05 ± 5.18 | 3.21 ± 2.71 | .805 | 3.05 ± 3.03 | 3.12 ± 3.16 | 2.45 ± 1.51 | .318 |
| TNF-a, pg/mL | 3.75 ± 3.98 | 3.77 ± 4.09 | 3.43 ± 2.15 | .512 | 3.99 ± 4.36 | 4.05 ± 4.51 | 3.48 ± 2.81 | .730 |
| MMP-9, pg/mL | 575.4 ± 412.21 | 569.56 ± 415.71 | 648.73 ± 365.61 | .376 | 572.02 ± 404.64 | 566.74 ± 396.24 | 619.52 ± 502.48 | .729 |
| BNP, pg/mL | 73.78 ± 128.2 | 69.04 ± 119.17 | 159.01 ± 224.76 | .032 | 82.88 ± 184.54 | 82.73 ± 189.25 | 85.61 ± 53.93 | .903 |
| NT-proBNP, pg/mL | 326.17 ± 508.26 | 309.84 ± 479.77 | 620.1 ± 833.47 | .045 | 333.98 ± 656.38 | 334.36 ± 667.06 | 327.16 ± 447.52 | .975 |
| CXCL16, pg/mL | 377.32 ± 184.6 | 378.74 ± 185.97 | 351.81 ± 158.17 | .422 | 400.7 ± 177.19 | 407.21 ± 176.96 | 283.47 ± 143.57 | .041 |
| Myeloperoxidase, ng/mL | 804.6 ± 608.31 | 790.15 ± 596.15 | 1064.66 ± 761.48 | .053 | 772.32 ± 578.49 | 781.05 ± 573.53 | 615.25 ± 679.94 | .404 |
| FABP3, pg/mL | 3897.16 ± 5052.61 | 3753.19 ± 4626.35 | 6488.74 ± 9775.58 | .126 | 3715.77 ± 4147.81 | 3754.21 ± 4255.32 | 3023.89 ± 778.65 | .091 |
| FABP4, pg/mL | 8862.78 ± 15535.85 | 8644.89 ± 15236.33 | 12784.73 ± 20083.51 | .259 | 7194.32 ± 9954.25 | 7404.6 ± 10147.59 | 3409.36 ± 4030.18 | .022 |
| LIGHT, pg/mL | 293.06 ± 508.32 | 297.34 ± 517.25 | 216 ± 300.69 | .164 | 255.62 ± 470.8 | 265.28 ± 481.53 | 81.62 ± 87.69 | .000 |
| NGAL, ng/mL | 492.19 ± 806.46 | 483.16 ± 797.36 | 654.74 ± 955.64 | .242 | 454.08 ± 819.81 | 466.28 ± 839.62 | 234.44 ± 193.62 | .017 |